1. Home
Board of Directors
TTY upholds integrity principles, emphasizes shareholder rights and principles, and firmly believes that a transparent and efficient board of directors is the cornerstone of corporate sustainability. The board elects persons with professional skills and expertise to form the highest governance body. Board members come from diverse backgrounds and the board itself has to meet basic criteria in the fields of operation modes, development demands, integrity principles in conformity to core corporate values, and professional skills and expertise. Board members have rich practical experience in the fields of business, finance, accounting, and the biomedical industry. Their background and experience enables the board to optimize the required board functions and capabilities. This enables the board to take full account of legal risks, eco-friendliness, labor, and social dimensions when facing major decisions to steer the company in the direction of sustainable operations.
The board of directors guides the company's strategy, supervises the management, and is responsible to the company and shareholders. The operations and arrangements of the corporate governance system ensure that the board of directors exercises its powers in accordance with laws, regulations of the company's articles of association, or resolutions of the shareholders' meeting.
Over the past years, TTY has gradually established a sound corporate governance system. In consideration of the fact that independent directors have no conflict of interest as far as company operations are concerned, they can provide objective and unbiased opinions based on their professionalism and independence during the board decision making process to ensure that diverse opinions are taken into account and to avoid the ivory tower syndrome. The appointment of independent directors is also conducive to monitoring of company operations and governance and safeguarding of shareholder rights and interests. As a result, three of the nine board members are independent directors and a candidate nomination system has been adopted. The board selects suitable candidates from the list of nominees. An Audit Committee and Remuneration Committee directly subordinate to the board were established. These two functional committees assist the board in the performance of duties in accordance with their authorities.
The Board of Directors are elected with its "Director Election Policy." The Board is comprised of nine members and three out of nice are independent directors.
Duration：2021.08.25~2024.08.24
Chairman LIN, CHUAN
►Education
　>Ph.D., Economics, University of Illinois at Urbana-Champaign, USA
►Current Employment
　>Chairman, TTY Biopharm Company Limited
►Professional background
　Mr. Lin has been being director since year 2011 and be Chairman since Jan/2018. He has plenty of industrial, public service, academy and international affair experience.
Vice Chairman CHANG, WEN-HWA
►Education
　>MBA of Manmos College
►Current Employment
　>Director, Arich Investment Co., Ltd.
►Professional background
　Ms. Chang has been being director since year 1995 and was familiar with finance operation and risk management in biotech industry.
Director HSIAO, CARL
►Education
　>PharmD, University of the Pacific Thomas J Long School of Pharmacy
　>MBA, University of the Pacific Eberhardt School of Business
►Current Employment
　>Director, TSH Biopharm Corporation Ltd.
　>Director, American Taiwan Biopharma Thailand Inc.
　>Director, Dawan Technology Company Limited
►Professional background
　Mr. Hsiao has been long-term employing in a large-chain retail pharmacy - CVS Health Pharmacy, with professional skills of pharmaceutical prescription management, clinical services, disease management planning and retail pharmacy management services.
Director YANG, TZE-KAING
►Education
　>MBA, University of Illinois at Urbana-Champaign, USA
　>Ph.D, Graduate School of Business Administration, National Chengchi University, Taiwan
►Current Employment
　>Chairman, Yangtze Associates
　>Director & President, Huiyang Private Equity Fund Co., Ltd.
　>Director, Chien Kuo Construction Co., Ltd.
　>Director, Airiti Co.
　>Director, Hon Yang Healthcare
　>Independent Director, DBS Bank (Taiwan) Ltd.
　>Director, Pegatron
　>Director, Taiwan Stock Exchange Corporation
　>Director, Asustek Computer Inc.
►Professional background
　Mr. Yang has been being director since year 2016 and was president of China Development Bank. He is also professor of Guanghua School of Management and ChengChi University with expertise of investment and financing.
Director XU, SHI-CHANG
►Education
　>EMBA, Master of Executive Management of National Chiao Tung University
　>BS., Department of Electrical Engineering, National Taiwan University
►Current Employment
　>Vice Chairman, Asustek Computer Inc.
　>Director, Pegatron Corporation
►Professional background
　Mr. Xu can make the best judgment at critical moments and complex situations and problems with his outstanding insights and observation. He can provide the efficiency & effective strategies for TTY, and comprehensive talent management during the sustainable transformation.
Director LIAO, YING-YING
►Education
　>MBA, University of Missouri, USA
►Current Employment
　>Director, cnYES.com Co., Ltd.
　>Director, Evenstar Master Fund SPC
►Professional background
　Ms. Liao has been being has been being supervisor and director since year 2014. She dedicated in global capital market for long run and be familiar with finance operation and risk management.
Independent Director HSUEH, MING-LING
►Education
　>MBA, Bloomsburg University, Pennsylvania, USA
　>MS., Graduate Institute of Accounting, Soochow University
►Current Employment
　>Independent Director, Yuanta Financial Holding Co., Ltd.
　>Independent Director, Yuanta Commercial Bank Company Limited
　>Independent Director, Lite-On Technology Corp.
　>Independent Director, Walsin Lihwa Corporation
　>Director, Tung Hua Book Co., Ltd.
►Professional background
　Mr. Hsueh has been being independent director since year 2016 and as and chairman of remuneration committee. He was chairman of PwC Taiwan. He is executive director of Taiwan Corporate Governance Association with expertise of finance, accounting, risk control and corporate governance.
Independent Director ZHENG, AN-LI
►Education
　>Ph.D., Graduate Institute of Clinical Medicine, National Taiwan University
►Current Employment
　>Distinguished Chair Professor, National Taiwan University
►Professional background
　Mr. Zheng has been elected as independent director in year 2024 and as member of remuneration committee, audit committee and sustainable development committee. He owns rich experience in medical management, industry, government and academia.
Independent Director CHANG, MING-DAO
►Education
　>MBA, Graduate School of Law, Chinese Culture University
►Current Employment
　>Chairman, Bank of Panhsin
　>Independent Director, PharmaEngine Inc.
►Professional background
　Mr. Chang has been elected as independent director in year 2024 and as a convener of audit committee. He has professional experience in banking industry.
2024.03.08
  1. Discussion about the Company's 2023 employees and managers remuneration.
  2. Proposal for the Company's 2023 distribution of remuneration to directors.
  3. The Company's 2023 business report and financial reports.
  4. Proposal of the Company's 2023 earnings appropriation.
  5. Proposal for nomination of candidates to be elected as directors (including independent directors) of the Company in 2024.
  6. Removal of non-compete restrictions for new directors and their representatives.
  7. Proposal of the Company's 2023 "Internal Control System Statement".
  8. Approval for the capital reserve transfer to capital increase and cash capital reduction and return of shares to shareholders.
  9. Approval for the subsidiary to acquire 51% of the outstanding common shares of Company A and Company B.
  10. Approval for amending the organizational charter.
  11. Proposal to amend the Company's "Rules of Procedure for Board of Directors Meetings".
  12. Proposal to amend the Company's "Audit Committee Charter".
  13. Approval for amending the Employee Stock Ownership Trust Regulations.
  14. Changes in the Company's personnel.
  15. Change of the Company's spokesperson and acting spokesperson.
  16. The Company's salary adjustment policy plan for 2024.
  17. Discussion about changes to the leave system for senior executives.
  18. Discussion about fixed monthly remuneration for the Chairman of the Company.
  19. Discussion about fixed monthly remuneration for the General Manager of the Company.
2023.12.15
  1. Approval for amending the organizational charter.
  2. Change of the Company's managerial officers.
  3. Approval of the Company's 2024 business plan and budget.
  4. Approval for the termination of the subsidiary's project development.
  5. Proposal for the Company to continue to purchase professional medical information service from IQVIA Ltd. and share the service expense with IQVIA Ltd.
  6. Approval for the Company's 2024 audit plan.
  7. The Company expects to appoint KPMG to provide non-assurance services in 2024.
  8. Appointment of CPAs, evaluation of independence and suitability, and fiscal and taxation audit fees of 2024.
  9. Proposal to amend the Company's "Procedures for Acquisition or Disposal of Assets".
  10. Approval for amending the "Regulations Governing Authority to Internal Approvals" of the Company.
2023.11.03
  1. Approval of asset impairment for the equipment of Chungli factory.
  2. The Company's consolidated financial reports for the third quarter of 2023.
  3. Approval for the 2024 work plan of the Company's Sustainable Development Committee.
  4. Proposal to formulate the "Procedures for Compilation and Verification of Sustainability Report".
2023.09.27
  1. Approval for amending the organizational charter.
  2. Resignation of the Company's manager.
  3. Proposal of the Company to engage managerial officers.
  4. Change of the Company's managerial officers.
2023.08.10
  1. The Company's consolidated financial reports for the second quarter of 2023.
  2. Review of the motion for product development expenses of the Company.
  3. Proposal to authorize the introduction of new drugs for cancer.
  4. Change of the transfer price of the Company's authorized subsidiary to distribute the agency products.
  5. Approval of the cash capital increase of the subsidiary.
  6. Proposal to amend the Company's "Corporate Governance Best Practice Principles".
  7. Proposal to amend the Company's "Related Party Transaction Procedures".
  8. Proposal to amend the Company's internal control system and internal audit system.
  9. Approval for amending the Articles of Incorporation.
  10. Proposal to distribute the remuneration for the directors appointed by the Company in subsidiaries and reinvested companies to exercise director functions and powers on behalf of the People's Republic of China in 2022.
  11. Discussion about distribution of remuneration to managers in 2022.
2023.07.28
  1. Proposal of the Company to engage managerial officers.
2023.05.05
  1. The Company's consolidated financial reports for the first quarter of 2023.
  2. Approval for amending the organizational charter.
  3. Approval for amending the "Regulations Governing Authority to Internal Approvals" of the Company.
  4. The Company intends to update some of the transaction conditions for authorizing the subsidiary to distribute drugs.
2023.03.14
  1. The Employees’ Compensation of the Company in 2022.
  2. The Directors’ Compensation of the Company in 2022.
  3. Year 2022 Business Report and Financial Report.
  4. Year 2022 Earnings Distribution Proposal.
  5. Planned Amendment of the Company’s “Articles of Incorporation”.
  6. Planned Amendment of the Company’s “Principles of Procedure of Shareholders’ Meeting”.
  7. Planned Amendment of the Company’s “Other management system- Management of prevention of insider trading”.
  8. Planned Amendments over The Company’s “Internal Approval Authority Guidelines”.
  9. Date, venue, and agenda for the year 2023 Annual General Meeting.
  10. Propose to Disposal of Inventory.
  11. Intended to increase budget for the re-construction of Plant Chungli.
  12. Proposal of change of trading terms for Invested Company’s distribution agency products under the Company’s authorization.
  13. Proposal to authorize a subsidiary to promote drugs of the Company.
  14. The invested Company has Commissioned the Company to Provide Professional Product Operating Management Services.
  15. Proposed to approve the Capital Reduction and Cash Refund of a Subsidiary.
  16. Formulation of the year 2022 Internal Control Statement.
  17. Formulation of “Schedule of Greenhouse Gas Inventory and Verification” of a Subsidiary and Regular Report to the Company.
  18. Proposal to In-license new oncology drug.
  19. 2023 Pay Raise Strategy.
  20. Discussion of Remuneration for the Company’s Independent Directors.
  21. Discussion of Fixed Remuneration for the Company’s Chairman.
  22. Discussion of Fixed Remuneration for the Company’s General Manager.
  23. Intention of a Subsidiary to Conduct Capital Reduction to Write Off Accumulated Losses.
2022.12.23
  1. Establishment of the Company’s year 2023 Operation Plan & Budget Proposal.
  2. Proposal of Change of New Business Model.
  3. Intended to In-licensing Oncology Drug X.
  4. Planned of Dissolution of oversea Company X.
  5. Intended to Authorize to Invested Company for the Negotiation of Contract and Transfer Price on the products which was distributed by the Invested Company.
  6. Commissioning of the Company by an invested company to provide product marketing research and investigation consulting services.
  7. Subsidiaries Leased Office from the Company.
  8. Planned formulation of the year 2023 Audit Plan.
  9. Planned Amendment of the Company’s “Organization Regulations”.
  10. Planned Amendment of the Company’s “Policy and Procedure of Risk Management”.
  11. Planned amendment of the Company’s “Procedure of Internal Material Information and Prevention of Insider Trade”.
  12. Planned formulation of “Principles of Pre-Approval Policy on Non-Assurance Service”.
  13. Commissioning of KPMG on regular assurance service and non-assurance service in year 2023.
  14. Year 2023 assessment of CPA independence and professional qualifications, CPA appointment, and financial and tax audit fees.
  15. Change of Managerial Officer.
2022.11.04
  1. The Consolidated Report for the third quarter of year 2022.
  2. Planned of Dissolution of oversea Company X.
  3. Proposal of Organization Adjustment.
  4. Planned Amendment of the Company’s “Organization Regulations”.
  5. Planned Amendment of the Company’s “Regulation of Subsidiary Management”.
  6. Planned Amendment of the Company’s “Rule of Procedure for Board of Meeting”.
  7. Planned Amendment of the Company’s “Other Management System- Operation Management of Board of Meeting”.
  8. Proposal of Change of Chief Auditor.
  9. Lifting of non-compete restrictions for the management.
2022.08.05
  1. The Consolidated Report for the second quarter of year 2022.
  2. Planned Amendments over the Company’s “Other Management System-Related Party Transaction” under Internal Control System and Internal Audit System.
  3. Planned to launch employee stock ownership trust of the Company.
  4. Intention to distribute compensation to the Company’s subsidiary director representative upon performance of the year 2021 director duty.
  5. Discussion over year 2021 Managerial Officers’ Remuneration Distribution.
2022.07.01
  1. Set up Ex-dividend Date and Payment Date.
  2. Planned Amendment of the Company’s “Operating Procedure of Transaction on Related party” .
2022.05.13
  1. Proposal of New Business Model.
  2. The Consolidated Report for the first quarter of year 2022.
  3. Commissioning of the Company by a Subsidiary to add new commissioned items for development.
  4. Intention of endorsement guarantee to a Subsidiary.
  5. Proposal to change the designation of the custodian of the company seal registered by the Ministry of Economic Affairs of the company.
  6. Planned formulation of “Schedule of Greenhouse Gas Inventory and Verification”.
2022.03.09
  1. Planned to subscribe Company X’s cash capital increase.
  2. Planned to change the distribution and transfer price of product X in Thailand.
  3. Planned amendment of the Company’s “Article of Incorporation”.
  4. Planned amendment of the Company’s “Operation Procedure of Acquisition and Disposal of Assets”.
  5. Intended to adjust the organization’s name and the title of salary structure table.
  6. Planned amendment of the Company’s “Organization Regulations”.
  7. Proposal of changes in the Company’s General Manager.
  8. Proposal of changes in the Company’s managerial officers.
  9. The Employees’ Compensation of the Company in 2021.
  10. The Directors’ Compensation of the Company in 2021.
  11. Year 2021 Business Report and Financial Report.
  12. Year 2021 Earnings Distribution Proposal.
  13. Date, venue, and agenda for the year 2022 Annual General Meeting.
  14. Formulation of the year 2021 Internal Control Statement.
  15. Year 2022 assessment of CPA independence and professional qualifications, CPA appointment, and financial and tax audit fees.
  16. 2022 Pay Raise Strategy.
  17. Discussion of Fixed Remuneration for the Company’s Chairman.
2021.12.24
  1. Establishment of the Company’s year 2022 Operation Plan & Budget Proposal.
  2. Intended to increase budget for the re-construction of Lioudu Plant.
  3. Propose to derecognize the overdue accounts receivables and related commissions payable for the Company’s oversea client from accounting.
  4. Planned amendment by a subsidiary about the leased office and adjustment of rental area from the Company.
  5. Planned formulation of the year 2022 Audit Plan.
  6. Planned amendment of the Company’s “Guidelines for Corporate Governance”.
  7. Planned amendment of the Company’s “Guidelines for Corporate Social Responsibility Practices”.
  8. Planned amendment of the Company’s “Operating Procedures for the Processing of Material Internal Information”.
  9. Planned amendment of the Company’s “Other management system- Management of prevention of insider trading”.
2021.12.03
  1. Lifting of non-compete restrictions for the management.
  2. Proposed to transfer intangible assets – drug license to other company and to sign a manufacturing contract.
2021.11.04
  1. The Consolidated Report for the third quarter of year 2021.
  2. Planned to increase budget of developing generic drug X.
  3. Proposal of change of transfer price for Invested Company’s distribution agency products under the Company’s authorization.
  4. Commissioning of the Company by the invested Company to Provide Product Marketing Research and Investigate Consulting Services and Professional Product Operating Management Services.
  5. Planned amendment of “Accounting rules” of the Company.
  6. Planned revision of “Other management- Process of Financial Statement Preparation” under internal control system.
  7. Planned formulation of “Procedures of Communications between Audit Committee and Auditing CPA”.
  8. Planned formulation of “Procedure s of Communications between Audit Committee and Internal Auditing Unit”.
  9. Intention to distribute compensation to the Company’s re-invested company director representative upon performance of the year 2020 director duty.
  10. Intended Amendment of the title on “The Salary Structure of Managers”.
  11. Intended Adjustment of the hiring list of the Company’s managerial officers.
2021.10.18
  1. Planned to Dismiss Mr. Shih, Chun-Liang as the Company’s General Manager.
  2. Planned Hiring Chairman Lin, Chuan as the Company’s General Manager.
  3. Planned to Dismiss Mr. Qu, Zhi-Yuan as the Company’s Vice President.
  4. Proposed to change the designation of the custodian of the Company seal registered in the Ministry of Economic Affairs.
2021.08.25
  1. Chairman and vice chairman recommended by directors.
  2. Appointment of members for the 3rd session of Auditing Committee of the Company and Appointment the convener of the 1st meeting for current session.
  3. Appointment of the members of the 5th session of Remuneration Committee of the Company and Appointment the convener of t1st meeting for current session.
  4. Appointment of the members of the 2nd session of Sustainable Development Committee of the Company and Appointment the convener of t1st meeting for current session.
  5. Set up Ex-dividend Date and Payment Date.
2021.08.05
  1. The Consolidated Report for the second quarter of year 2021.
  2. Planned Amendments over the Company’s “Internal Approval Authority Table”.
  3. Planned to Re-schedule the Date and Venue of the year 2021 Annual General Meeting.
  4. Planned to develop generic drug X and establish its production line.
  5. Proposal of subsidiary’s intention to commission the Company in new drug development.
  6. Planned to conduct royalties payment for API (Active Pharmaceutical Ingredients).
  7. Commissioning of the Company by an invested company to manufacture investigational drugs, conduct necessary trials and validation, and the Company also out-licensing the distribution of the products.
  8. Planned to change the certain transaction terms for a subsidiary’s distributed products under the Company’s authorization.
  9. Discussion over year 2020 Managerial Officers’ Remuneration Distribution.
  10. Intention to distribute compensation to the Company’s subsidiary director representative upon performance of the year 2020 director duty.
2021.05.06
  1. The Consolidated Report for the first quarter of year 2021.
  2. Planned Amendment of the Company’s “Best Practices of Corporate Social Responsibility”.
  3. Commissioning of the Company by a Subsidiary to Provide Human Resource Service.
  4. The Budget for the Company’s Product Development.
2021.04.23
  1. Commissioning of the Company by a Subsidiary to Provide Legal Service.
  2. Proposal of Adding Appropriation of Special Surplus Reserve in accordance with the Regulation of Financial Supervisory Commission.
  3. Planned Nomination of the list of Directors (including Independent Directors) for the 2021 Election of Directors.
  4. The Release of non-compete restrictions for new-elected director and its representative.
2021.03.19
  1. Proposal of Upgrade of Injection Facility in Chungli Plant.
  2. Proposal of Improvement of Microspheres Facility in Lioudu Plant.
  3. The Employees’ Compensation of the Company in 2020.
  4. The Directors’ Compensation of the Company in 2020.
  5. Year 2020 Business Report and Financial Report.
  6. Year 2020 Earnings Distribution Proposal.
  7. Year 2021 assessment of CPA independence and professional qualifications, CPA appointment, and financial and tax audit fees.
  8. Formulation of the year 2018 Internal Control Statement.
  9. Planned Amendment of the Company’s “Regulation of election of directors”.
  10. Planned Amendment of the Company’s “Organization Regulations for Sustainable Development Committee”.
  11. Proposal of Change of Acting Spokesperson.
  12. Proposal of Change and Designation of the Custodian of the Company’s Seal Registered in the Ministry of Economic Affairs.
  13. Planned Commissioning of the Company by a Subsidiary to Provide Logistics Management Service.
  14. Proposal of Renewal of Professional Medical Information Provided by IQVIA AG and the Expense Shared by the Re-invested Company.
  15. 2021 Pay Raise Strategy.
  16. Discussion of Fixed Remuneration for the Company’s General Manager.
  17. Discussion of Fixed Remuneration for the Company’s Chairman.
2021.02.05
  1. The Re-election of the Company’s directors and independent directors.
  2. Date, venue, and agenda for the year 2021 Annual General Shareholders’ Meeting.
  3. Planned to sign Licensing Agreement with Partners.
  4. Planned to Co-develop European Market of Pegylipo with Germany Pharmaceutical Company.
2020.12.28
  1. Establishment of the Company’s year 2020 Operation Plan & Budget Proposal.
  2. Planned to Purchase of “Patent Search System” and “Comprehensive Competitive Intelligence Database”.
  3. Subsidiaries Leased Office from the Company.
  4. Subsidiary’s Intention to Commission the Company to Provide Drug Inspection and Registration Service.
  5. Invested Company’s Commissioning the Company to Provide the Company with Human Resource Service.
  6. The Establishment of the Company’s “Risk Management Policies and Procedures”.
  7. Amendment of The Company’s “The Salary Structure for Managers”.
  8. The Amendment of partial terms of licensing contract for the Company’s acquisition of exclusive distribution right of X product in Taiwan.
2020.11.20
  1. Proposal of Hiring a Vice President and the Change of R&D Manager.
  2. Planned to Enter a Supplementary Agreement for Licensing Contract with a Subsidiary.
2020.11.03
  1. Proposal of Contract Renewal for Subsidiary’s Commissioning the Company on Drug Manufacturing.
  2. The invested Company has Commissioned the Company to Provide Product Marketing Research and Investigate Consulting Services and Professional Product Operating Management Services.
  3. Proposal of Subsidiary’s Distribution Products Authorized by the Company.
  4. Planned Commissioning of the Company by a Subsidiary to Provide IT services.
  5. Planned formulation of the year 2020 Audit Plan.
  6. The Amendment of the Company’s “Other Management System-Management of Capital Loan to Others”.
  7. The Amendment of the Company’s Internal Control System.
  8. Discussion over year 2021 Management Personnel’s Remuneration Distribution.
2020.08.03
  1. Planned Commissioning of the Company by a Subsidiary to Provide Legal services.
  2. Planned Commissioning of the Company by a Subsidiary to Provide Logistics Management Services.
  3. The Amendment of the Company’s “Corporate Governance Best Practice Principles”.
  4. The Amendment of the Company’s “Corporate Social Responsibility Best Practice Principles”.
  5. The Amendment of the Company’s “Rules Governing the Scope of Powers of Independent Directors”.
  6. The Amendment of the Company’s “Performance Assessment Guidelines for Board of Directors and Functional Committee”.
  7. The Establishment of the Company’s “Regulation of Merger & Acquisition information reveal discipline”.
  8. The Amendment the "Remuneration Committee Charter".
  9. Intention to distribute compensation to the Company’s assigned re-invested company director representative upon performance of the year 2019 director duty.
  10. Proposal of Distribution of Special Bonus for manager personnel in 2019.
  11. Discussion of remuneration for General Manager.
  • Discussion of monthly remuneration for Chairman.
  • The Overdue Accounts Receivables of the Company’s Oversea Customers are not categorized as Lending Funds.
2020.06.29
  1. Proposal of Subsidiary’s Distribution Products Authorized by The Company.
  2. Proposal of Participating in Re-invested Company’s Issuance of Common Stock.
  3. Proposal of Change of partial transaction terms for Subsidiary’s Commissioning the Company to Produce Drugs.
  4. Set up Ex-dividend Date and Payment Date.
  5. Appointment of Members for the 4th Term of the Remuneration Committee.
  6. Hiring Mr. Shih, Chun-Liang as the General Manager of the Company.
2020.05.05
  1. Proposal of Increased Expense for Land Purchase.
  2. The Company’s Intention to Develop Generic Drug.
  3. Intended Offshore Investment to Establish Subsidiary.
  4. Re-Appointment and Appointment of Subsidiary’s Legal Person Director Representative.
  5. Lifting of non-compete restrictions for the management.
  6. Proposal of 2020 Assessment of Attesting CPA’s Retainment, Independence and Competence and Audit Fee for Finance/Tax Compliance Audit.
  7. The amendment of “Articles of Incorporation”.
  8. The amendment of “Rules of Procedure for Board of Directors Meetings”.
  9. The amendment of “Audit Committee Charter”.
  10. 2020 Manager Performance Reward Program.
  11. Discussion of Salary and Remuneration for The Company’s Chief Operating Officer.
2020.03.16
  1. Proposal of Intended Purchase of Land.
  2. Appointing Invested Company’s Director Representative.
  3. The Company’s Intended Commitment to KPMG International for Support of Subsidiary’s Continued Operations.
  4. Intended Loan to Invested Company.
  5. Proposal of The Company’s 2019 Employee Remuneration Distribution.
  6. Proposal of The Company’s 2019 Director Remuneration Distribution.
  7. 2019 Business Report and financial statements.
  8. 2019 Profit Distribution.
  9. The amendment of “Articles of Incorporation”.
  10. The amendment of “Rules of Procedure for Shareholders Meetings”.
  11. The amendment of “Regulations for Lending Funds to Other Parties”.
  12. The amendment of “Procedures and Guidance for Ethical Operation Conduct”.
  13. Date, Location and Agenda for Convening the Company’s 2020 Shareholders’ Meeting.
  14. Planned Drafting of The Company’s 2019 “Internal Control System Statement”.
  15. The Company’s 2020 Salary Adjustment Proposal.
  16. 2019 Manager Performance Reward Proposal.
  17. Planned Distribution of 2019 Special Contribution Program Rewards.
  18. Planned Appointment of Vice General Manager Shih, Chun-Liang for The Post of Chief Operating Officer.
  19. Planned amendments over The Company’s “Internal Approval Authority Guidelines”.
2019.12.27
  1. Planned Increase of Budget for Developing Antibiotic New Product.
  2. Invested Company’s Commissioning The Company to Provide the Company with logistic management service.
  3. Planned amendments over The Company’s “Internal Approval Authority Guidelines”.
  4. Establishment of the Company’s 2020 Operation Plan & Budget Proposal.
  5. Proposal of Requesting Chairman’s Authorization to Dispose Invested Shares.
  6. Subsidiary’s Intention to Commission The Company to Provide Management Consulting Service.
  7. Planned Increase of Additional Budget for Product Production Process Development and Establishment of Production Equipment.
2019.11.13
  1. 2019 assessment of CPA independence and professional qualifications, CPA appointment, and financial and tax audit fees.
  2. Planned formulation of the 2020 Audit Plan.
  3. The establishment of “Regulation of Transfer of Repurchased Shares to Employee”.
  4. Intended Subscription of Invested Company’s New Shares Issued from Cash Capital Increase.
  5. Intended Purchase of Invested Company’s Shares Owned by Invested Company’s Shareholders.
  6. Subsidiary’s Intention to Terminate Offshore Exclusive Authorization for The Company’s Certain Drug.
  7. Proposal of Change of Transaction Terms for Subsidiary’s Commissioning The Company to Produce Drugs.
  8. Subsidiary’s Intention to Commission The Company to Provide Drug Inspection and Registration Service.
  9. Proposal of Change of Transfer Price for Invested Company’s Distribution Agency Products Under The Company’s Authorization.
  10. Proposal of transportation allowance for commissioners of the Company’s Sustainable Development Committee attending Sustainable Development Committee meeting..
2019.10.07
  1. Proposal of Change of Subsidiary’s Director and Supervisor Representatives.
  2. Planned Drafting of The Company’s “Organization Regulations for Sustainable Development Committee”.
  3. Planned Company’s Commissioning for Establishment of The First Plenary Sustainable Development Committee.
  4. The amendment of “Ethical Corporate Management Best Practice Principles”.
  5. The amendment of “Procedures and Guidance for Ethical Operation Conduct”.
  6. Planned amendments of The Company’s “Property, Plant and Equipment Cycle” and “Other Management System – Management of Capital Loan to Others”.
  7. Planned amendment of The Company’s Performance Assessment Guidelines for Board of Directors and Functional Committee.
  8. Discussion over 2018 Management Personnel’s Remuneration Distribution.
2019.09.04
  1. Planned to Obtain Invested Company’s Common Shares from Open Market.
2019.08.12
  1. Proposal of Changes in The Company’s R&D Management.
  2. Proposal of The Company’s Re-Appointment of Invested Company’s Legal Person Director Representative.
  3. Lifting of non-compete restrictions for the management.
  4. Planned Company’s Commissioning of The Company to Provide Logistics Management Service.
  5. Planned issue of compensations in 2018 for the exercise of functions and powers by director representatives of investees designated by the Company.
  6. Discussion of 2018 Manager’s Special Bonus Distribution Plan.
  7. Intended Capital Loan to Invested Company.
2019.06.25
  1. The Company’s Intention to Work with Major International Manufacturers in Exploring Octreotide LAR Generic Drug’s Offshore Market.
  2. Subsidiary Leased Office from The Company and Entered Lease Agreement accordingly.
  3. Proposal of increase in Subsidiary’s Distribution Products Authorized by The Company.
  4. Intended establishment of cash dividend ex-dividend date and distribution date.
  5. Proposal of appointing Invested Company’s Director Representative.
  6. Lifting of non-compete restrictions for the management.
  7. Deliberation of Chairman Compensation.
  8. Planned amendments of partial conditions for seeking of international company product’s Exclusive Agency in Taiwan area.
2019.05.10
  1. Lifting of non-competition restrictions for directors.
  2. Proposal to add an Annual General Shareholders’ Meeting in 2019.
  3. Planned formulation of Standard Procedures Governing the Handling of Director Requests.
  4. 2019 Manager Sales Target Bonus Proposal.
  5. Revision of agency authorizations and trading partners for the Company’s drugs in overseas areas.
  6. Discussion of appointment and compensations for new managers.
2019.03.26
  1. Total employee and director compensation and individual compensation for directors in 2018.
  2. 2018 Business Report and Financial Statements.
  3. 2018 Earnings Distribution Proposal.
  4. Planned amendment of the Procedures for Acquisition or Disposal of Assets.
  5. Planned amendment of the Regulations for Lending Funds to Other Parties.
  6. Planned amendment of the Regulations on Endorsement & Guarantee.
  7. Date, venue, and agenda for the 2019 Annual General Shareholders’ Meeting.
  8. Formulation of the 2018 Internal Control Statement.
  9. Internal audit officer appointment.
  10. Corporate governance officer appointment.
  11. Planned commissioning of the Company by a subsidiary to provide logistics management services.
  12. 2018 Manager Sales Target Bonus Proposal.
  13. Planned issue of incentive bonuses for the 2018 special contribution project.
  14. Planned replacement of juristic person director representative for a subsidiary.
  15. Authorization of agents for distribution of the Company’s drugs in overseas areas.
2019.02.25
  1. Planned acquisition of exclusive agency rights for the products of an international company in the Taiwan area.
  2. Planned amendment of the Company’s Corporate Governance Best Practice Principles.
2019.01.11
  1. Formulation of the 2019 Business Plan and budget.
  2. 2018 Pay raise strategy.
  3. Planned issue of special bonuses to managers in 2018.
2018.12.24
  1. Planned payment of a commission to a subsidiary for the commissioning of the Company to manufacture drugs.
  2. Planned authorization of a investee as an agent for drugs manufactured by the Company.
  3. Lending of funds to subsidiaries.
  4. Planned amendment of the Audit Committee Charter of the Company.
  5. Planned revision of the internal control system of the Company.
  6. Planned formulation of the 2018 Audit Plan.
  7. Planned dissolution of the TTY Biopharm Taipei Branch.
  8. Appointment of the General Manager for a subsidiary.
  9. Appointment of the members of the 4th Remuneration Committee.
  10. Dismissal of the audit officer due to position adjustment.
  11. Consultant appointment.
2018.11.22
  1. Chairman and vice chairman recommended by directors.
  2. Appointment of second audit committee of the company.
2018.11.14
  1. Independence and competency of CPA, appointment of CPA and fee for financial/taxation audit.
  2. Commercial terms revision for commissioned products manufacturing agreement between subsidiary and the company.
  3. Investee commissions the company to provide IT service.
  4. Investee leased office from the company and sign rental agreement.
  5. Investee intends to commission the company to provide market research and consultancy service.
2018.10.26
  1. Review nominated directors (independent directors included) nominated by shareholders who holds more than 1%.
  2. To release the non-competition of directors and representatives.
  3. To amend the agenda of first extraordinary general meeting for year 2018.
2018.10.04
  1. The company authorizes the investee to revise partial transaction terms on distributed products.
  2. Assign holders of registered seals.
  3. Discussion on management and employment compensation allocation.
  4. To commission partner to execute In-vitro test.
  5. Beforehand reelection of all directors and independent directors.
  6. To amend “article of the incorporation”.
2018.09.17
  1. The company would take Taiwan’s CED consultant and clinical trial for global pharma company.
  2. Investee intends to commission the company to provide market research and consultancy service.
  3. Investee intends to commission the company to provide professional service.
  4. To pay the compensation to representatives of the directors assigned by the company for year 2017.
  5. Discussion of special bonus of management for year 2017.
  6. Discussion for reply to court on effectiveness of contracts.
2018.08.13
  1. To amend “valuation of performance for functional committee and board of directors”.
  2. To amend joint venture agreement between the company and partner.
  3. Subsidiary intends to commission the company to provide administration affair service.
  4. Assignment of directors and chairman for subsidiary.
  5. To pay the compensation to representatives of the directors assigned by the company for year 2017.
2018.06.20
  1. Set up ex-dividend date and payment date.
  2. To develop certain generic drug for overseas markets with a global pharma company.
  3. Agree partner to change re trial company to execute application for drug license for overseas markets.
  4. To authorize invested company to distribute more products.
  5. Change of representatives of directors/supervisors for subsidiaries.
  6. To conceal business registration of overseas subsidiary.
  7. To authorize Chairman to dispose invested shares in public market.
  8. Subsidiary intends to invest a 100% owned company.
2018.05.14
  1. Proposal of the Company’s collaboration with stakeholder.
  2. Proposal of the Company’s paying bonus to collaborating partner.
  3. Proposal of refunding product price difference to invested company.
  4. Proposal to adjust transfer prices on invested company’s distribution product.
  5. Proposal of subsidiary’s commissioning the Company to provide logistic management service.
  6. Proposal of factory transfer on products commissioned by subsidiary.
  7. Proposal to reserve part of subsidiary’s retained earnings from being distributed.
  8. Proposal of authorizing Chairman to dispose re-invested company’s shares.
2018.03.29
  1. The Company’s 2017 employee, director and supervisor compensation total amount and individual compensation distribution for director and supervisor.
  2. The Company’s 2017 business report and financial statement proposal.
  3. Proposal of the Company's 2017 profit distribution.
  4. Proposal of assigning subsidiary director representative selection.
  5. Proposal of modifying the Company’s “Subsidiary Management Guidelines”.
  6. Proposal of intention to establish the Company’s “Procedures for Ethical Management and Guidelines for Conduct”.
  7. Date, location and agenda for the Company’s 2018 shareholders’ Regular meeting.
  8. Proposal of factory transfer for subsidiary’s commissioned product manufacturing.
  9. Proposal of intention to purchase professional medical information service.
  10. Drafting of the Company’s 2017 “Internal Control System Statement”.
  11. Proposal of intention to distribute the Company’s 2017 special contribution reward bonus.
  12. The Company’s salary adjustment strategy for 2018.
  13. Proposal of modifying the Company’s compensation structure chart.
  14. Discussion of manager’s Salary and Compensation.
  15. Proposal of the Company’s 2018 budget modification.
2018.02.05
  1. Proposal of establishing the Company’s 2018 operation plan and budget.
  2. In response to initial adoption of International Financial Reporting Standard #9, proposal to transfer original classification of “equity tool reserved for selling financial asset” to the classification of “financial asset measured in fair value through other consolidated income.”
  3. Proposal to set up offshore subsidiary
  4. Proposal of cancelling non-competition restrictions on managers.
  5. Proposal of intention to distribute management 2017 bonus.
  6. Proposal of 2018 enterprise management incentive plan.
  7. Discussion of manager’s Salary and Compensation.
  8. Discussion of the Company chairman’s 2018 remuneration.
  9. Proposal of intention to purchase equipment
2018.01.19
  1. Proposal of change of legal person director representative for invested company.
2018.01.15(extraordinary)
  1. Proposal of electing the Company’s chairman.
  2. Proposal of the Company’s retaining of general manager.
2018.01.15
  1. Proposal of establishing the Company’s 2018 operation plan and budget.
  2. Proposal of invested company’s commissioning the Company for 2018 information service.
  3. Proposal of contract renewal for subsidiary’s commissioning the Company on drug manufacturing.
  4. Proposal of newly added items for authorized subsidiary’s distribution of products.
  5. Proposal of invested company’s sharing of information services and service fee with the Company.
  6. Proposal of authorized transfer price changes on invested company’s distributed products.
2017.12.13
  1. Proposal of the Company’s intention to execute offshore clinical test for certain product.
  2. Proposal of the Company’s authorization to invested company on distribution product price change.
  3. Discussion of litigation case to the former Chairman.
2017.11.13
  1. Proposal of subsidiary’s intention to establish branch office in Taiwan.
  2. Proposal of intention to increase budget needed for product offshore market development and supplementary entering of agreement with collaboration partner.
  3. Proposal of project budget for the Company’s intention to develop new antibiotic product.
  4. Assessment of independence and adequacy for 2016 certified accountants, and commissioning of certified accountants, and proposal for finance audit of public expense.
  5. Proposal of modifying the Company’s “Rules Governing the Scope of Powers of Independent Directors”.
  6. Proposal of modifying the Company’s internal control system and internal audit system.
  7. Proposal of intention to establish the Company’s 2018 audit plan.
  8. Discussion of manager’s Salary and Compensation.
  9. Discussion of the Company’s 2016 manager and employee compensation distribution.
  10. Proposal of authorizing Chairman to dispose re-invested company’s shares.
2017.10.31
  1. Proposal of authorizing Chairman to dispose re-invested company’s shares.
2017.10.03
  1. Proposal of subsidiary’s intention to commission the Company to assist in new drug development.
  2. Proposal of intention to increase experiment execution expenses with respect to the Company’s collaboration with strategic partner on joint developing product offshore markets.
  3. Proposal of subsidiary’s commissioning the Company to conduct comparison experiment between its product and competitive products.
  4. Proposal of intention to increase clinical test expense from the Company’s execution of post market monitoring clinical test.
  5. Proposal of the Company’s intention to execute factor transfer for fungal infection treatment drugs, develop and test on excipient ingredient change and increase in developing oral dosage generic drug for similar products.
  6. Proposal of the Company’s intention to establish subsidiary for offshore investment.
  7. Proposal to the Company’s intention to change designation of directors/supervisors of the Company’ s subsidiaries.
  8. Proposal of improvement construction for Chungli factory storage area.
2017.08.14
  1. Proposal of the Company’s intention to develop product manufacturing process amplification and establishment of clinical test production equipment.
  2. Proposal of subsidiary’s intention to rent office from the Company and to commission the Company to provide logistics management service.
  3. Proposal of certain trading term modifications from the Company’s authorizing invested company for product distribution.
  4. Proposal of the Company’s scrapping of raw material, finished product and commodity inventory.
  5. Proposal of modifying the Company’s “Regulations Governing Procedure for Board of Directors Meetings”.
  6. Proposal of modifying the Company’s “Audit Committee Organization Rules”.
  7. Intention to distribute compensation to the Company’s assigned re-invested company director representative upon performance of 2016 director duty.
  8. 2016 management special bonus distribution plan.
2017.06.16
  1. Proposal of intention to establish cash dividend ex-interest base date and distribution date.
  2. Proposal of changes on investment structure and capital input planning for invested company.
2017.05.03
  1. Proposal of executing the product budget of a clinical test project.
  2. Proposal of assisting directors/supervisors to re-invested company.
  3. Lifting of the ban on participation in competitive business by directors.
  4. Lifting of the ban on participation in competitive business by managers.
  5. Proposal of 2017 promotion for Senior Managers.
  6. Proposal of entering contract with a certain company of related rights on agreed product and technology development.
2017.04.05
  1. Proposal of the Company’s intention to establish a joint venture with 2-BBB MEDICINES BV to develop liposome new drug “Glutathione Pegylated Liposomal Methylprednisolone Injection (2B3-201)”.
  2. Proposal of intention to maintain subsidiary’s drug permit and enter drug permit license depository agreement.
  3. Proposal of intention to designate director representative selection for re-invested company.
2017.03.22
  1. Proposal of the Company’s intention to re-designate director representative for subsidiary.
  2. Proposal of cancelling non-competition restrictions on managers.
  3. Proposal to change the Company’s spokesman.
2017.03.10
  1. The Company’s 2016 employee, director and supervisor compensation total amount and individual compensation distribution for director and supervisor.
  2. The Company’s 2016 business report and financial statements.
  3. Proposal of the Company’s 2016 profit distribution.
  4. Proposal of intention to modify the Company’s “Articles of Incorporation”.
  5. Proposal of intention to modify the Company’s “Asset Acquisition or Disposal Handling Procedures”.
  6. Proposal of intention to modify the Company’s internal control system and internal audit system.
  7. Proposal of intention to draft the Company’s 2016 “Internal Control System Statement”.
  8. Proposal of cancelling director non-competition restrictions.
  9. Date, venue and agenda for the Company’s holding of 2017 shareholders’ regular meeting.
  10. Proposal of intended modification of designation procedures for re-invested company’s director representative.
  11. Proposal of intended increase of experiment execution expense for the Company’s collaboration with major international companies in developing liposome product offshore markets.
  12. Proposal of intended distribution of the Company’s 2016 special contribution reward bonus.
  13. Proposal of intention to enter contract with a certain company.
2017.02.07
  1. Proposal of intention to modify the Company’s “Internal Approval Authorization Guidelines”.
  2. Proposal of establishing the Company’s 2017 operation plan and budget.
  3. Proposal of amendment to the Company’s obtainment of Italy MolMed Company authorization of exclusive distribution rights of cell treatment drug “Zalmoxis®” in Asia.
  4. Proposal of the Company’s commissioning a certain company to complete the Company’s drug toxicology and pharmacology test and obtainment of import permit.
  5. Proposal of the Company’s intention to obtain subsidiary’s certain drug offshore exclusive distribution rights.
  6. Re-invested company’s entering of house leasing contract with the Company for renting office.
  7. The Company’s salary adjustment strategy for 2017.
  8. Proposal of intention to distribute 2015 employee compensation and 2016 yearend special bonus to Taipei branch office managers.
  9. Proposal of intention to terminate drug development and commissioned production collaboration with a certain company.
2016.12.29
  1. Obtainment of Italy MolMed Company authorization of exclusive distribution rights of cell treatment drug “Zalmoxis®” in Asia regions of Taiwan, Hong Kong, Vietnam, Philippines, Thailand, Malaysia and Singapore.
  2. Proposal of the Company’s execution of a certain clinical test project budget.
  3. Proposal of modifying the Company’s “Corporate Governance Principles”.
  4. Proposal of modifying the Company’s “Corporate Social Responsibility Best Practice Principles” and “Corporate Social Responsibility Policy”.
  5. Proposal of modifying the Company’s “Ethical Corporate Management Best Practice Principles”.
  6. Proposal of drafting the Company’s “Performance Assessment Guidelines for Board of Directors’ Meeting and Functional Committees”.
  7. Proposal of authorizing Chairman to dispose re-invested company’s shares.
  8. Proposal of the Company’s intention to obtain loan from 100% wholly owned subsidiary.
  9. Extension of subsidiary’s loan.
  10. Proposal of re-invested company’s commissioning of 2017 information service to the Company.
  11. Proposal of the Company’s related rights on agreed product development, licensing fee and technology development with a certain company.
  12. Proposal of amendment to the Company’s authorizing re-invested company to distribute products.
2016.11.11
  1. Proposal to modify the Company’s “Application for Suspending and Resumption of Transaction Operation Procedure”.
  2. Proposal of modifying the Company’s “Internal Major Information Processing Procedures”.
  3. Proposal of modifying the Company’s “Guidelines for Selection and Review of Certified Accountant”.
  4. Assessment of independence and adequacy for 2016 certified accountants, and commissioning of certified accountants, and proposal for finance audit of public expense.
  5. Proposal of drafting the Company’s 2017 audit plan.
  6. Proposal of conducting consolidation operations between Taipei subsidiary and Headquarters.
  7. Proposal of modifying contract documents with respect to the Company’s commissioning of a certain company to complete drug toxicology and pharmacology tests and obtain drug import permit.
  8. Proposal of entering “Consultant Service Contract” from the Company’s provision of product development consulting service to re-invested company.
  9. Proposal of entering “Professional Service Contract” from the Company’s provision of professional services to re-invested company.
  10. Proposal of subsidiary’s commissioning of the Company to proceed with clinical product trial production.
2016.09.30
  1. Proposal of adding, deleting and changing transfer price and product items for the Company’s products distributed by authorized re-invested company and modifications on some transaction terms.
  2. Proposal of adding new products to the Company’s authorizing subsidiary to distribute products.
  3. Proposal of the Company’s intention to obtain Taiho Pharmaceutical Co., Ltd. cancer fighting drug「Lonsurf (TAS-102)」 Taiwan market exclusive authorized distribution.
  4. Proposal of the Company’s intention to commission some company to complete the Company’s drug toxicology and pharmacology test and obtain import drug permit.
  5. Proposal of increasing clinical test expense for the Company’s conducting liposome product post-market surveillance clinical test.
  6. Proposal of the Company’s cancer translation center moving to Shi Zi Farglory U-Town business building.
  7. Intention to distribute compensation to the Company’s assigned re-invested company director representative upon performance of 2015 director duty.
  8. Proposal of the Company’s intention to modify “Guidelines for Director and Supervisor Compensation Distribution”.
  9. Proposal of intention to cancel the Company’s “Business and Office Car Allowance for Managers”.
  10. Submission of manager car allowance proposal.
  11. Proposal of the Company’s 2015 manager and employee compensation distribution.
  12. Budget proposal for the Company’s conducting of certain clinical test project.
2016.08.12
  1. The company’s 2015 director/supervisor compensation distribution proposal.
  2. Discussion of transportation allowances for directors attending the meeting of board of directors.
  3. Discussion of transportation allowances for auditors attending the audit committee meeting.
  4. Subsidy proposal for the company manager’s business and service car.
  5. The company’s commission of CRO Company in conducting human equivalence clinical trials on liposome product.
  6. Proposal of entering Supplementary Agreement with CRO Company to conduct liposome product clinical trial.
  7. Proposal of participating in re-invested company’s issuance of common stock.
2016.07.04
  1. Proposal of developing the overseas market for liposome products in cooperation with well-established international pharmaceutical firms.
  2. Proposal of authorizing its subsidiaries to distribute the drugs developed by this company.
  3. Proposal of fixing the record date of the ex-cash dividend and cash dividend payment date.
  4. Proposal of planning of the distribution of performance bonus to outstanding managers for 2015.
  5. Discussion of transportation allowances for directors attending the board of director meeting.
  6. Discussion of transportation allowances for auditors attending the audit committee meeting.
  7. Discussion of compensations for the independent directors.
2016.06.24
  1. Election of the Chairman and Vice Chairman of the Board.
  2. Proposal of changing the appointment of directors of subsidiaries.
  3. Appointment of the members of the auditing committee of the first term.
  4. Amendment to the "Remuneration Committee Charter".
  5. Appointment of the members of the third-term Remuneration Committee.
2016.06.17
  1. Amendment to the "Rules of Procedure for Shareholder Meetings".
  2. Proposal of establishing the "Rules Governing the Scope of Powers of Independent Directors".
  3. Proposal of establishing the "Audit Committee Charter".
  4. Proposal of establishing the "Internal Control Regulation and other Management Systems" and "Internal Auditing System".
  5. Election of representatives to serve in the board of directors of subsidiary and sub-subsidiary.
  6. Resolution of the “TOT Biopharm Project Termination and Warrant Agreement” with related party.
  7. Proposal of authorizing the chairman of the board to claim the rights associated with the company's products and technologies.
2016.05.10
  1. Proposal of establishing the "Comparison table- editing, reviewing and authority of approval for internal control documents".
  2. Review of the candidates list of independent directors nominated by the shareholders meeting of 2016.
  3. Amendment to the "Articles of Incorporation".
  4. Amendment to the "Operational Procedures for Loaning Funds to Others".
  5. Amendment to the "Regulations Governing Endorsements/Guarantees".
  6. Amendment to the "Procedures for Election of Directors and Supervisors".
  7. Amendment to the "Internal Control System-other Management Systems" and "Internal Auditing System".
  8. IT Service to re-invested company.
  9. Proposal of entering supplementary to premises lease agreement with related party.
  10. Execution of “Consultation Service Agreement” with re-invested company.
  11. Appointment of directors of re-invested company.
  12. Proposal of assigning additional representative of director of re-invested company.
2016.04.28
  1. List of nominated independent director candidates.
  2. Election of director representatives at joint ventures.
  3. Handed out souvenirs at the 2016 General Shareholders’ Meeting.
2016.03.30
  1. 2015 Employee and Director/Supervisor Compensation Plan.
  2. 2015 Business Report and Financial Statement.
  3. 2015 Surplus Distribution Proposal.
  4. Amendment of the Procedures Governing the Handling of Derivative Transactions.
  5. Amendment of Subsidiary Management Guidelines.
  6. Amendment of the Internal Control System-Other Management Systems and the Internal Audit System.
  7. Formulation of the 2015 Internal Control System Statement.
  8. Full reelection of the board of directors.
  9. Lifting of the ban on participation in competitive business by newly appointed directors and their representatives.
  10. Date, location, and agenda of the 2016 General Shareholders’ Meeting.
  11. Appraisal of attesting accountants in 2015.
  12. Appointment of director representatives at joint ventures.
  13. Purchase of equipment from joint ventures.
  14. Technology transfer services and disbursement of expenses of the Company by joint ventures.
  15. Lease of office space from the Company by a joint venture.
2016.02.17
  1. Amendment of the Articles of Incorporation.
  2. Review of the 2016 salary adjustment policy by the remuneration committee.
  3. Review of the 2015 Incentive Plan for Special Contributions by the remuneration committee.
2015.12.31
  1. Review of the 2016 budget.
  2. Formulation of the Plan to Enhance the Company’s Ability to Compose its own Financial Statements.
  3. Formulation of the 2016 Internal Audit Plan.
  4. Amendment of the internal control system and relevant guidelines.
  5. Formulation of the Corporate Governance Principles.
  6. Hiring of a CFO and replacement of finance officer.
  7. Appointment of an acting spokesperson.
  8. Modification of the business scope of a subsidiary.
  9. Renewal of the lease of office space from the Company by a joint venture.
  10. Provisional seizure of the property of a certain director and compulsory enforcement by the Company as per ruling of the Taipei District Court.
2015.11.12
  1. Report on Consolidated Financial Statement for Q3 2015.
  2. Formulation of Operating Procedures Governing Applications for Suspension and Resumption of Transactions.
  3. Routine Transactions between the Company and related parties.
  4. Storage of samples for clinical trials by joint ventures and commissioned research services.
  5. Planned sale of the total equity held in TOT Biopharm International Company Limited through the subsidiary Xudonghaipu International Company Limited.
  6. Lifting of the ban on participation in competitive business by directors.
2015.10.27
  1. Appointment procedures for representatives of juridical person directors at joint ventures.
  2. Sale of the total equity held in TOT Biopharm International Company Limited through the subsidiary Xudonghaipu International Company Limited.
  3. Commissioning of the Company by a joint venture to provide information services.
2015.10.16
  1. Commissioning of the Company by a subsidiary to conduct trial production and development of products.
  2. Renewal of the lease of housing from a related party.
  3. Termination of exclusive agency rights of a subsidiary for a certain product of this company in Mainland China and authorization of the chairman to search for a suitable agent for said area.
2015.08.13
  1. Report on Consolidated Financial Statement for Q2 2015.
  2. Commissioning of a related party by the Company to manufacture pharmaceuticals.
  3. Appointment and dismissal of accounting managers.
  4. Appointment of a replacement member for the remuneration committee.
  5. Review of the compensation for directors/supervisors in 2014 by the remuneration committee.
  6. Review of granted employee bonuses and performance-based bonuses for managers in 2014 by the remuneration committee.
2015.07.16
  1. The Company becomes a distributor and agent for the Multiple Myeloma Drug “Aplidin” produced by the Spanish firm PHARMA MAR S.A. in the Taiwan region.
  2. Sale of the total equity held in Taiwan Tungyang International Company Limited through the subsidiary Xudonghaipu Pharmaceutical Company Limited.
  3. Planned loan from a subsidiary due to capital transfer.
  4. Signing of a Consultancy Service Agreement with a joint venture.
2015.06.16
  1. Determination of the ex-dividend date and issuance date of cash dividends.
  2. Increase of financing lines at financial institutions.
2015.05.13
  1. Report on the Consolidated Financial Statement for Q1 2015.
  2. Commissioning of the Company by a subsidiary to manufacture pharmaceuticals.
  3. Commissioning of the Company by a joint venture to manufacture pharmaceuticals.
  4. Transfer of the domain name registered with Asia Pacific Telecom by the Company to a joint venture.
2015.04.15
  1. 2014 surplus distribution proposal.
  2. Amendment of the Articles of Incorporation.
  3. Addition of proposals for the 2015 General Shareholders’ Meeting.
  4. Participation in share subscription in the context of cash capital increase of joint ventures.
  5. Promotion of Chen, De-Li Senior Vice President of the Critical Care Product Development Group to Vice General Manager.
  6. Suggestion of souvenirs for the 2015 General Shareholders’ Meeting.
2015.03.25
  1. Commissioning of the Company by a subsidiary to manufacture pharmaceuticals.
  2. Commissioning of the Company by a subsidiary to provide legal services.
  3. 2014 Business Report and Financial Statement.
  4. Review of the compensation for directors/supervisors and employee cash bonus allocation in 2014 by the remuneration committee.
  5. Lifting of the ban on participation in competitive business by directors.
  6. Date, location, and agenda of the 2015 General Shareholders’ Meeting.
  7. Formulation of the 2014 Internal Control System Statement.
  8. Planned participation in subsidiary cash capita increase.
  9. Appointment of director representatives for joint ventures of the Company.
  10. Commissioning of the Company by a related party to carry out R&D and trial of pharmaceuticals.
  11. Routine transactions between the Company and related parties.
2015.02.25
  1. A subsidiary commissions the Company to provide warehouse management and logistics services for pharmaceuticals.
  2. Commissioning of another company to carry out clinical trials.
  3. Review by the remuneration committee of the plan to grant bonuses for special contributions by managers in 2014.
  4. Review of the 2015 promotion and salary adjustment policies by the remuneration committee.
  5. Exclusive authorization of technology transfer and development of a certain technology in cooperation with the National Health Research Institutes.
2015.01.26
  1. Appointment procedures for representatives of juridical person directors at joint ventures.
  2. Confirmation of matters pertaining to the lawsuit filed by the supervisor on behalf of the Company.
2015.01.16
  1. Modification of review procedures for attesting accounting firms and accountants.
2015.01.08
  1. The Company files a lawsuit against a former manager.
2014.12.31
  1. Investment and manufacturing services entrusted by reinvestment companies.
  2. Proposal for altering pharmaceutics items licensed to distributors of subsidiaries.
  3. Examination of annual budget for ROC year 104.
  4. Revision of “Rules governing the conduct of Board Meeting”.
  5. Proposal for altering the custodian of stamp seal from Ministry of Economic Affairs.
  6. Authorization of reinvestment company stock disposal to our chairman.
2014.11.13
  1. Revision and expansion of “Internal Control System and Audit Checklist”.
  2. Stipulation of “ROC Year 104 Annual Internal Audit Project”.
  3. Authorization of reinvestment company stock disposal to our chairman.
  4. Transactions with affiliated stakeholders.
  5. Proposal for business address change of Taipei branch.
2014.10.31
  1. Establishment of structure and condition for certain pharmaceutics co-developed with Japanese company.
  2. Proposal for merger between reinvestment company and other corporates.
  3. Consideration and examination of retirement pension payment for ex-general manager by Compensation Committee.
  4. Consideration and examination of re-amendment of salary structure chart for the entire staff crew by Compensation Committee.
2014.09.30
  1. Proposal for election for the purpose of appointing board representatives of reinvestment company.
  2. Proposal for altering the chairman of reinvestment company.
  3. Proposal for replacing manager (administrator) of Taipei branch.
  4. Authorization of reinvestment company stock disposal to our chairman.
  5. Additional parking space rental for subsidiaries.
  6. Product trial-manufacture development entrusted by subsidiaries.
  7. Authorization of conducting processes related to certain pharmaceutics sales in Taiwan and contract-signing to our chairman.
  8. Proposal for pharmaceutics research and development trial services entrusted by reinvestment company.
2014.08.12
  1. Signing of “Commission of Manufacture Contract” with affiliated corporates.
  2. Consideration and examination of ROC year 102 annual supervisors’ compensations by Compensation Committee.
  3. Consideration and examination of annual staff bonus/manager commission distribution for ROC year 102 by Compensation Committee.
  4. Setting transportation compensation for board members/supervisors upon attending board meetings by Compensation Committee.
  5. Setting transportation compensation for members of Compensation Committee upon attending committee meetings.
  6. Establishment of structure and conditions for certain pharmaceutics co-developed with Japanese company.
  7. Proposal for certain subsidiaries’ participation in capital increase by cash of certain reinvestment company.
  8. Proposal for taking loans from subsidiaries due to fund dispatching.
  9. Proposal for reinvestment company stock disposal.
  10. Release of non-competition restriction on manager.
  11. Proposal for changing the representative supervisors for second-tier subsidiaries.
  12. Signing of “Consultation Service Contract” with reinvestment company.
  13. Transactions of intellectual property service and patent transfer with affiliated stakeholders.
  14. Proposal for product distribution contract signing with affiliated corporations.
  15. Proposal for equipment sales to reinvestment company.
  16. Proposal for certain pharmaceutics research and development entrusted by reinvestment company.
2014.06.24
  1. Nomination of chairman and vice-chairman for our company.
  2. Appointment of committee member for the second annual Compensation Committee.
  3. Proposal for authorizing chairman to set base day for ex-dividend of cash dividends, and base day for capital increase stock distribution.
  4. Re-appointment of board directors of subsidiaries.
2014.05.07
  1. Amendment to the “Procedures for Acquisition or Disposal of Assets”.
  2. Merger between reinvestment company and other corporations.
  3. Transactions with affiliated stakeholders.
  4. Research services entrusted by subsidiaries.
  5. Proposal for capital loaning from subsidiaries to second-tier subsidiaries.
  6. Appointment of board member representatives of reinvestment company.
  7. Proposal for advising souvenir distribution on the shareholders meeting held in the year of supervisor re-election.
2014.03.25
  1. Certain pharmaceutics research and development entrusted by affiliated corporations.
  2. Transactions with affiliated stakeholders.
  3. Appointment of board member representatives for subsidiaries.
  4. Company financial statement, combined financial report, and business report of ROC year 102.
  5. Discussion of proposal for ROC year 102 director and supervisor compensation and employee cash bonus by the Compensation Committee.
  6. Discussion of ROC year 103 promotion and raise standards, proposal of manager promotion and raise by the Compensation Committee.
  7. Proposal for make-up appointment of a member for the Compensation Committee.
  8. Surplus allotment for ROC year 102.
  9. Reelection of the directors of board and supervisors.
  10. Release of the non-competition restriction on new directors of board and their representatives.
  11. Dates, location and agenda of shareholder meetings for ROC year 103.
  12. Proposal for establishing the “Internal Control System Statement” for ROC year 102.
  13. Proposal for altering the company nominated accountant for the purpose of financial statement certification.
2014.02.20
  1. Disposal of real estate in Shanghai owned by reinvestment company.
  2. Involvement in reinvestment company’s cash capital increase for share subscriptions.
2014.01.08
  1. Examination of annual budget for ROC year 103.
  2. Transactions with subsidiaries.
  3. Proposal for increasing hedge fund and loan margins set by financial institutions.
  4. Terms of trade with reinvestment company for proposed product co-development in mainland China.
2013.12.17
  1. To sell the liposome equipment at the Chungli factory to the investee.
  2. Continued progress on a project.
  3. Budget for the new microsphere factory at the Lioudu factory.
  4. Ratification of the "2014 internal audit plan".
  5. To cooperate with the investee on the development of a certain product in China.
2013.11.12
  1. 2013 Q3 consolidated quarterly financial statement.
  2. Building lease contract entered into between TTY and the investee.
  3. Agreements on the amendments to the lease contract entered into between TTY and the investee.
  4. Donation to the hospital of Taipei Medical University by TTY.
  5. Additional purchase of B1 tunnel-type bottle washing, sterilization, and serum filling machines for the Chungli factory.
  6. Proposed participation of TTY in the offer of shares for the increase of capital at the investee by a subsidiary.
  7. To sell the shares of an investee to a subsidiary.
  8. Addition construction items at the Lioudu factory and their budget.
  9. The revision of the compensation structure for employees by the Compensation Committee of TTY.
2013.09.17
  1. The agreement on work orders between TTY and affiliated companies.
  2. The building lease contract between TTY and affiliated companies.
  3. Agreements on the amendments to the lease contract entered into between TTY and the subsidiary.
  4. TTY's participation in the offer of shares for capital increase at the investee.
  5. TTY's proposed licensing agreement with a certain company.
  6. To purchase formulation R&D equipment.
  7. The contract manufacturing items that the subsidiary plans to contract TTY to produce.
  8. Personnel changes for the finance and accounting supervisors of TTY.
2013.08.08
  1. 2012 Q2 consolidated quarterly financial statement.
  2. Additional expenses for the renovation construction aimed at increasing the volume of liposome products at the Chungli factory.
  3. Technical consulting provided by TTY’s employees to the investee.
  4. IT service agreement entered into by TTY and the subsidiary.
  5. TTY's borrowing of funds from subsidiary Xudong Haipu Internation Co., Ltd.
  6. TTY's proposed borrowing of funds from subsidiary Worldco International Limited for the reason of cash management.
  7. Review of the distribution of compensation for Directors and Supervisors in 2012 by the Compensation Committee.
  8. Review of the distribution of employee bonus and performance incentive for managers in 2012 by the Compensation Committee.
  9. To appoint an additional Compensation Committee member.
  10. pital increase by cash in a secondary subsidiary by a primary subsidiary.
2013.07.16
  1. TTY's participation in the offering of shares for the capital increase of CY Biotechnology Co., Ltd.
  2. To authorize the Chairman to designate the basis date for dividend distribution.
  3. The contract on the borrowing of equipment without compensation entered into between TTY and affiliated corporations.
  4. The technical written order signed by TTY and affiliated corporations.
  5. The work order signed by TTY and affiliated corporations.
  6. Proposed capital increase by cash of an investee.
2013.05.08
  1. 2013 Q1 consolidated quarterly financial statement.
  2. Report on the progress of IFRS conversion.
  3. Appointment of board representative at a certain investee.
  4. Transactions between TTY and its related parties.
2013.03.26
  1. 2012 Financial statements, consolidated financial statements, and business report.
  2. Distribution of 2012 compensation for Directors and Supervisors and cash bonus for employees.
  3. 2012 dividend distribution.
  4. The issue of new shares by appropriating 2012 earnings as increase in capital.
  5. The date of convening the 2013 Annual General Stockholders’ Meeting, meeting agenda and submission period of shareholder proposal.
  6. The proposal of releasing Directors from non-competition restrictions.
  7. Proposal for establishing the “Internal Control System Statement” for ROC year 103.
  8. The amendment to TTY's "Articles of Incorporation".
  9. The amendment to TTY's "Regulations on Endorsements and Guarantees".
  10. The amendment to TTY's "Regulations on Lending Funds to Other Parties".
  11. Entering into a contract service agreement by TTY and a certain affiliated company.
  12. TTY's proposal to change the appointment of the directors and supervisors of investees.
  13. Reviewing the performance evaluation and the distribution of incentive for managers in 2012.
  14. Reviewing the overall promotion and changes in salary regulations for the company overall in 2012 and the promotion and change in salary for managers.
  15. Proposed participation of TTY in the offer of shares for the increase of capital at the investee by a subsidiary.
2013.01.08
  1. Reviewing TTY's 2013 budget plan.
  2. To sell some of the shares in Shanghai Xudong Haipu Pharmaceutical Co., Ltd, in which our company indirectly invested.
2012.12.28
  1. 本公司於六堵廠設立針劑廠。
  2. 提高設定融資額度及借款額度。
  3. 修訂本公司「會計制度」案。
  4. 修訂本公司「關係人交易作業程序」案。
  5. 修訂本公司「內部控制制度作業及稽核項目」案。
  6. 訂定本公司「2013年度內部稽核計畫」案。
  7. 修改分公司績效獎金核發時間。
2012.10.26
  1. 2013年第3季之財務報表及合併財務報表報告。
  2. 本公司IFRS轉換進度報告。
  3. 中壢工廠廠房改建工程追加費用案。
  4. 本公司之子公司收購大陸公司100%股權案。
  5. 修訂本公司「董事會議事規範」案。
  6. 本公司人事晉升案。
2012.08.30
  1. 2012年上半年度之財務報表及合併財務報表。
  2. 本公司藥品授權轉投資公司經銷案。
  3. 更新整修中壢工廠設備。
  4. 向銀行申請OBU外債借款額度。
  5. 薪酬委員會審議2011年度董監酬勞案。
  6. 薪酬委員會審議2011年度員工分紅暨經理人績效獎金發放案。
  7. 本公司持有之轉投資公司股票不提撥作過額配售。
2012.07.09
  1. 本公司IFRS轉換進度報告。
  2. 新購機器設備案。
  3. 中壢工廠廠房改建工程案。
  4. 轉投資公司財務印鑑章處理案。
  5. 與子公司簽訂之委託開發契約修正契約書內容案。
  6. 本公司之子公司增資案。
  7. 海外子公司對其子公司之股權出售，修正收款方式及交割日期案。
2012.04.27
  1. 2012年第一季之財務報表及合併財務報表。
  2. 2011年度內部控制聲明書。
  3. 本公司處分轉投資公司股票案。
  4. 聘任稽核主管，負責內部稽核工作等業務案。
  5. 任命稽核人員代理人案。
  6. 本公司參與轉投資公司之現金增資案。
  7. 本公司擬訂定薪資報酬委員之出席報酬案。
2012.03.28
  1. 本公司IFRS轉換進度報告。
  2. 海外子公司對其子公司之股權出售，展延買方買權半年案。
  3. 本公司2011年度財務報表及合併財務報表。
  4. 本公司2011年度盈餘分配案。
  5. 本公2011年度盈餘轉增資發行新股案。
  6. 本公司2012年股東常會召開日期、地點及召集事由。
  7. 解除經理人競業禁止限制案。
  8. 聘任財務長，負責公司財務及會計等業務案。
  9. 解除董事競業禁止限制案。
  10. 本公司與某公司擬簽訂專利授權轉移及委託新藥開發管理合約案。
2012.03.20
  1. 修訂本公司「子公司管理辦法」案。
  2. 修訂本公司「內部控制制度作業及稽核項目」案。
  3. 修訂本公司「2012年稽核計劃」案。

TOP